Morgan Stanley initiated coverage on Abivax SA with a new price target
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $12.00 | Equal-Weight | Morgan Stanley |
| 12/4/2024 | $33.00 | Mkt Outperform | JMP Securities |
| 7/29/2024 | $48.00 | Buy | Laidlaw |
| 5/20/2024 | $43.00 | Buy | BTIG Research |
| 4/29/2024 | $42.00 | Overweight | Piper Sandler |
| 4/29/2024 | $50.00 | Buy | Guggenheim |
| 11/14/2023 | $15.00 | Equal-Weight | Morgan Stanley |
| 11/14/2023 | $20.00 | Outperform | Leerink Partners |
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC
Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00
JMP Securities initiated coverage of Abivax SA with a rating of Mkt Outperform and set a new price target of $33.00
Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00
SC 13G/A - Abivax S.A. (0001956827) (Subject)
SC 13G - Abivax S.A. (0001956827) (Subject)
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-
6-K - Abivax S.A. (0001956827) (Filer)
SCHEDULE 13G - Abivax S.A. (0001956827) (Subject)
S-8 - Abivax S.A. (0001956827) (Filer)